These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. The thrombin activation pathway modulates the assembly, structure and lysis of human plasma clots in vitro. Torbet J. Thromb Haemost; 1995 May; 73(5):785-92. PubMed ID: 7482404 [Abstract] [Full Text] [Related]
31. Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor. Nielsen VG. Blood Coagul Fibrinolysis; 2008 Jun; 19(4):283-7. PubMed ID: 18469549 [Abstract] [Full Text] [Related]
36. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B. Hosaka Y, Takahashi Y, Ishii H. Thromb Haemost; 1998 Feb 31; 79(2):371-7. PubMed ID: 9493593 [Abstract] [Full Text] [Related]
37. [Effects of cimetidine and ranitidine on blood coagulation]. Lübcke P, Herrmann W. Dtsch Med Wochenschr; 1982 Nov 05; 107(44):1671-4. PubMed ID: 6291889 [Abstract] [Full Text] [Related]
40. Quantification of the effects of thrombin activatable fibrinolysis inhibitor and alpha2-antiplasmin on fibrinolysis in normal human plasma. Nielsen VG, Ellis TC. Blood Coagul Fibrinolysis; 2007 Jan 05; 18(1):29-33. PubMed ID: 17179823 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]